ong-term survival and vascular event risk after young TIA or stroke: a prospective cohort study.
- Conditions
- cerebrovascular diseasestroke100110821000796310003216
- Registration Number
- NL-OMON31828
- Lead Sponsor
- niversitair Medisch Centrum Sint Radboud
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 600
Inclusion Criteria
- young TIA or stroke: ever occurrence of TIA or stroke > 18 years but < 45 years.
- neurological analysis at the UMC St Radboud
Exclusion Criteria
none
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>mortality<br /><br>incident (cerebro) vascular disease<br /><br>incident (vascular) dementia</p><br>
- Secondary Outcome Measures
Name Time Method <p>atherosclerosis (as assessed with an ultrasound of the carotid arteries), blood<br /><br>pressure, cognitive function and quality of life.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What genetic biomarkers predict long-term survival in young stroke patients enrolled in NL-OMON31828?
How does vascular event risk in young TIA/stroke patients compare to standard risk models in NL-OMON31828?
What molecular pathways are associated with secondary stroke prevention in young patients according to NL-OMON31828 findings?
Are specific inflammatory biomarkers (e.g., CRP, IL-6) linked to adverse outcomes in young cerebrovascular disease patients in this study?
What role do antiplatelet therapies (e.g., aspirin, clopidogrel) play in reducing vascular events among young stroke survivors in NL-OMON31828?